• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

正常眼压性青光眼的治疗

The treatment of normal-tension glaucoma.

作者信息

Desai Priya V, Caprioli Joseph

机构信息

Jules Stein Eye Institute, UCLA, 100 Stein Plaza, Suite 2-118, Los Angeles, CA 90095, USA.

出版信息

Prog Brain Res. 2008;173:195-210. doi: 10.1016/S0079-6123(08)01114-X.

DOI:10.1016/S0079-6123(08)01114-X
PMID:18929110
Abstract

Normal-tension glaucoma (NTG) is generally defined as visual field loss and optic nerve defects consistent with glaucoma and an intraocular pressure (IOP) that does not exceed 21 mmHg (Allingham, R.R., Damji, K., Freedman, S., Moroi, S., Shafranov, G., Shields, M.B. (2005). In: Pine J. and Murphy J. (Eds.), Shields' Textbook of Glaucoma, 5th edn., Lippincott Williams & Wilkins, Philadelphia, PA, pp. 197-207, Chapter 11). If a patient has an atypical presentation (unilateral disease, decreased central visual acuity or visual field loss not consistent with optic disk appearance) then the clinician should rule out medical or neurologic etiologies. IOP-dependent and IOP-independent mechanisms play a role in NTG nerve damage. The exact mechanisms of IOP-independent damage are not currently known. Research has shown that vascular etiologies, such as vascular insufficiency and vasospasm, may be possible mechanisms for IOP-independent damage. The mainstay of glaucoma treatment remains robust IOP reduction. The chief goal of ongoing glaucoma research is to more clearly identify IOP-independent mechanisms of damage and to find neuroprotective treatment strategies to prevent retinal ganglion cell death and consequent visual loss.

摘要

正常眼压性青光眼(NTG)通常被定义为与青光眼相符的视野缺损和视神经损害,且眼压(IOP)不超过21 mmHg(Allingham, R.R., Damji, K., Freedman, S., Moroi, S., Shafranov, G., Shields, M.B.(2005年)。载于:Pine J.和Murphy J.(编),《Shields青光眼教科书》,第5版,Lippincott Williams & Wilkins出版社,宾夕法尼亚州费城,第197 - 207页,第11章)。如果患者有非典型表现(单侧疾病、中心视力下降或视野缺损与视盘外观不符),那么临床医生应排除医学或神经学病因。眼压依赖性和非眼压依赖性机制在NTG神经损伤中起作用。目前尚不清楚非眼压依赖性损伤的确切机制。研究表明,血管病因,如血管供血不足和血管痉挛,可能是非眼压依赖性损伤的潜在机制。青光眼治疗的主要方法仍然是有效降低眼压。当前青光眼研究的主要目标是更明确地确定非眼压依赖性损伤机制,并找到神经保护治疗策略,以防止视网膜神经节细胞死亡及随之而来的视力丧失。

相似文献

1
The treatment of normal-tension glaucoma.正常眼压性青光眼的治疗
Prog Brain Res. 2008;173:195-210. doi: 10.1016/S0079-6123(08)01114-X.
2
Optic disc and visual field changes after trabeculectomy.小梁切除术后的视盘和视野变化。
Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4693-9. doi: 10.1167/iovs.08-3115. Epub 2009 May 27.
3
Scleral edge, not optic disc or retina, is the primary site of injury in chronic glaucoma.巩膜边缘而非视盘或视网膜,是慢性青光眼的主要损伤部位。
Med Hypotheses. 2006;67(6):1320-5. doi: 10.1016/j.mehy.2006.05.030. Epub 2006 Jul 7.
4
Normal-tension glaucoma: is it different from primary open-angle glaucoma?正常眼压性青光眼:它与原发性开角型青光眼不同吗?
Curr Opin Ophthalmol. 2008 Mar;19(2):85-8. doi: 10.1097/ICU.0b013e3282f3919b.
5
Reversal of optic disc cupping in glaucoma.青光眼视盘杯状凹陷的逆转
Br J Ophthalmol. 2008 Jul;92(7):901-5. doi: 10.1136/bjo.2007.135350.
6
The potential role of glutamate transporters in the pathogenesis of normal tension glaucoma.谷氨酸转运体在正常眼压性青光眼发病机制中的潜在作用。
J Clin Invest. 2007 Jul;117(7):1763-70. doi: 10.1172/JCI30178.
7
[Clinical approach to normal intraocular pressure glaucoma].[正常眼压性青光眼的临床诊疗方法]
Acta Med Croatica. 2005;59(2):123-8.
8
[Retinal ganglion cells death in glaucoma--mechanism and potential treatment. Part II].[青光眼视网膜神经节细胞死亡——机制与潜在治疗。第二部分]
Klin Oczna. 2007;109(7-9):353-5.
9
Role of cerebrospinal fluid in glaucoma: pressure and beyond.脑脊液在青光眼发病机制中的作用:压力及其他。
Med Hypotheses. 2010 Jan;74(1):31-4. doi: 10.1016/j.mehy.2009.08.024. Epub 2009 Oct 9.
10
Glaucoma as a neurodegenerative disease.青光眼作为一种神经退行性疾病。
Curr Opin Ophthalmol. 2007 Mar;18(2):110-4. doi: 10.1097/ICU.0b013e3280895aea.

引用本文的文献

1
Edaravone suppresses retinal ganglion cell death in a mouse model of normal tension glaucoma.依达拉奉抑制正常眼压型青光眼小鼠模型中的视网膜神经节细胞死亡。
Cell Death Dis. 2017 Jul 13;8(7):e2934. doi: 10.1038/cddis.2017.341.
2
[Current aspects on the management of normal tension glaucoma].[正常眼压性青光眼治疗的当前进展]
Ophthalmologe. 2015 Nov;112(11):943-54; quiz 955-6. doi: 10.1007/s00347-015-0140-5.
3
Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis.治疗青光眼、年龄相关性黄斑变性和葡萄膜炎的新兴疗法的近期专利
Recent Pat Biomed Eng. 2012 Apr 1;5(1):83-101. doi: 10.2174/1874764711205010083.
4
Brimonidine prevents neurodegeneration in a mouse model of normal tension glaucoma.溴莫尼定可预防正常眼压性青光眼小鼠模型中的神经退行性变。
Cell Death Dis. 2014 Jul 17;5(7):e1341. doi: 10.1038/cddis.2014.306.
5
Renin-angiotensin system regulates neurodegeneration in a mouse model of normal tension glaucoma.肾素-血管紧张素系统在正常眼压性青光眼小鼠模型中调节神经退行性变。
Cell Death Dis. 2014 Jul 17;5(7):e1333. doi: 10.1038/cddis.2014.296.
6
Activation of muscarinic receptors protects against retinal neurons damage and optic nerve degeneration in vitro and in vivo models.毒蕈碱型乙酰胆碱受体激动剂可保护体外和体内模型中的视网膜神经元免受损伤和视神经变性。
CNS Neurosci Ther. 2014 Mar;20(3):227-36. doi: 10.1111/cns.12187. Epub 2013 Nov 27.
7
Novel ocular antihypertensive compounds in clinical trials.处于临床试验阶段的新型眼部抗高血压化合物。
Clin Ophthalmol. 2011;5:667-77. doi: 10.2147/OPTH.S15971. Epub 2011 May 20.